Print Page | Close Page

 
 

BlueWhale Bio

Address: 2929 Arch Street, Philadelphia, PA 19104
 
Country: USA
 
Sectors: Collaborations & Partnerships- R&D, Collaborations & Partnerships-Services, Collaborations & Partnerships-Manufacture, Proprietary Research & Manufacture, Contract Manufacturing, Contract Research & Development
 
Website: https://bluewhale.bio
 
- - -
 

About Us

BlueWhale Bio is dedicated to accelerating the growth and adoption of cell-based therapies. With the demand for cell therapy products surpassing supply, BlueWhale Bio aims to address critical shortcomings in the current treatment paradigm. The company is developing a portfolio of groundbreaking products that bring the full benefits of cell therapy to more patients faster and at lower costs. For the Synecta™ platform, we focus on activation and expansion, as this early stage in the cell therapy manufacturing process defines which cells can be effectively processed and sets the stage for the efficiency and simplicity of all downstream steps.

 
- - -
 

Sectors

  • Collaborations & Partnerships- R&D
  • Collaborations & Partnerships-Services
  • Collaborations & Partnerships-Manufacture
 
  • Proprietary Research & Manufacture
  • Contract Manufacturing
  • Contract Research & Development
 
- - -
 

Categories

  • Biologics
  • Cell Therapy
  • Cell Therapy Products
  • Nanoparticles
  • Bioprocess Development
 
  • Bioprocessing
  • Platform Technology-Drug Development
  • Platform Technology-Drug Discovery
  • T-Cells
  • CAR-T Therapies
 
- - -
 

News

 
22nd October 2025
 

Avantor® and BlueWhale Bio Partner to Accelerate CAR-T Manufacturing

 

RADNOR, Pa. and PHILADELPHIA, Oct. 15, 2025 — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced a strategic partnership with BlueWhale Bio, a commercial-stage company dedicated to transforming immune cell therapy manufacturing and addressing the unmet need in CAR-T production by streamlining manufacturing, reducing variability, and shortening time-to-patient.


The partnership combines Avantor’s bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio’s Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics natural T-cell stimulation. The collaboration aims to accelerate CDNP manufacturing scale-up to help CAR-T developers significantly reduce expansion time – potentially expanding patient access and manufacturing capacity across the growing cell therapy sector. Together, the teams will produce GMP-grade CDNP materials to support this next-generation manufacturing approach.

 
- - -
 
Printed: 16-Mar-2026 at 05:19:46 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com